Analysts Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Target Price at $41.17

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been assigned an average rating of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $41.1667.

Several research firms recently weighed in on KNSA. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Wells Fargo & Company upped their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 9th. Jefferies Financial Group upped their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Finally, Wedbush restated an “outperform” rating and issued a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 18,889 shares of the stock in a transaction on Monday, August 4th. The stock was sold at an average price of $32.89, for a total transaction of $621,259.21. Following the sale, the chief financial officer directly owned 27,009 shares in the company, valued at approximately $888,326.01. This trade represents a 41.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Thomas Malley sold 78,233 shares of the stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total value of $2,588,729.97. Following the sale, the director owned 12,546 shares in the company, valued at approximately $415,147.14. This represents a 86.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 593,416 shares of company stock worth $18,924,806 over the last three months. Corporate insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Several institutional investors have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC boosted its stake in Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after purchasing an additional 532 shares during the last quarter. Corebridge Financial Inc. boosted its stake in Kiniksa Pharmaceuticals International by 3.6% during the 1st quarter. Corebridge Financial Inc. now owns 15,979 shares of the company’s stock valued at $355,000 after purchasing an additional 549 shares during the last quarter. GAMMA Investing LLC boosted its stake in Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after purchasing an additional 568 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its stake in Kiniksa Pharmaceuticals International by 4.0% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company’s stock valued at $326,000 after purchasing an additional 568 shares during the last quarter. Finally, Martingale Asset Management L P boosted its stake in Kiniksa Pharmaceuticals International by 1.3% during the 1st quarter. Martingale Asset Management L P now owns 50,000 shares of the company’s stock valued at $1,111,000 after purchasing an additional 640 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Stock Performance

KNSA stock opened at $33.70 on Thursday. Kiniksa Pharmaceuticals International has a fifty-two week low of $17.82 and a fifty-two week high of $34.55. The business’s 50 day moving average price is $30.10 and its two-hundred day moving average price is $25.77. The company has a market capitalization of $2.50 billion, a price-to-earnings ratio of 842.71 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.